Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

1.7K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Spatial architecture contributes to failure of bulk biomarker-guided neoadjuvant immunotherapy selection in bladder cancer: The DUTRENEO study.

Cell reports. Medicine·2026
Same author

Enfortumab vedotin in ECOG-PS 2 advanced urothelial carcinoma patients: a real-world study from the ARON-2<sup>EV</sup> project.

BMC cancer·2026
Same author

Real-world comparison of the effectiveness and safety of immune-based combinations in elderly patients with advanced renal cell carcinoma (ARON-1 study).

Minerva urology and nephrology·2026
Same author

Lipidomic profiling in metastatic prostate cancer captures tumor metabolic rewiring and its modulation by androgen receptor-targeting therapy.

Prostate cancer and prostatic diseases·2026
Same author

Patient selection for triplet therapy with darolutamide in metastatic castration-sensitive prostate cancer and patterns of administration: a Spanish multicenter study.

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·2026
Same author

Efficacy, toxicity, and clinical outcomes of 177Lu-PSMA-617 radioligand therapy at 5.5 GBq per cycle in patients with advanced castration-resistant prostate cancer: a prospective, single arm, phase II study.

European journal of nuclear medicine and molecular imaging·2025

Related Experiment Video

Updated: Jan 14, 2026

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
11:02

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

21.7K

ctDNA-Guided Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer.

Thomas Powles1, Ariel G Kann2, Daniel Castellano3

  • 1Barts Cancer Institute, National Institute for Health Research Biomedical Research Centre, Queen Mary University of London, London.

The New England Journal of Medicine
|October 22, 2025
PubMed
Summary

Circulating tumor DNA (ctDNA) testing identified patients with muscle-invasive bladder cancer who benefited from atezolizumab. This ctDNA-guided immunotherapy significantly improved disease-free and overall survival post-cystectomy.

More Related Videos

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

10.9K
An Orthotopic Bladder Cancer Model for Gene Delivery Studies
07:48

An Orthotopic Bladder Cancer Model for Gene Delivery Studies

Published on: December 1, 2013

13.0K

Related Experiment Videos

Last Updated: Jan 14, 2026

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
11:02

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

21.7K
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

10.9K
An Orthotopic Bladder Cancer Model for Gene Delivery Studies
07:48

An Orthotopic Bladder Cancer Model for Gene Delivery Studies

Published on: December 1, 2013

13.0K

Area of Science:

  • Oncology
  • Genomics
  • Clinical Trials

Background:

  • Muscle-invasive bladder cancer (MIBC) outcomes vary significantly after cystectomy.
  • Circulating tumor DNA (ctDNA) detection of molecular residual disease can identify high-risk patients.
  • Adjuvant immunotherapy guided by ctDNA may improve outcomes and reduce treatment burden.

Purpose of the Study:

  • To evaluate the efficacy of ctDNA-guided adjuvant atezolizumab in patients with MIBC post-cystectomy.
  • To assess the impact of ctDNA status on disease-free survival (DFS) and overall survival (OS).

Main Methods:

  • Phase 3, double-blind, randomized trial using serial ctDNA testing for surveillance.
  • ctDNA-positive patients were randomized (2:1) to atezolizumab or placebo for up to 1 year.
  • Primary endpoint: investigator-assessed DFS; Secondary endpoint: OS.

Main Results:

  • Atezolizumab significantly improved median DFS (9.9 vs. 4.8 months) and OS (32.8 vs. 21.1 months) compared to placebo.
  • Hazard ratios for recurrence/death and death were 0.64 and 0.59, respectively.
  • Patients persistently ctDNA-negative had high DFS rates (95% at 1 year, 88% at 2 years).

Conclusions:

  • ctDNA-guided adjuvant therapy with atezolizumab significantly enhances DFS and OS in MIBC patients.
  • This approach identifies patients likely to benefit from immunotherapy, sparing others unnecessary treatment.
  • The study provides a framework for ctDNA-guided treatment decisions in bladder cancer management.